Skip to main content

Guido Ferrari, MD

Guido Ferrari, MD
Associate Professor of Surgery
Associate Research Professor in Molecular Genetics and Microbiology
Office: 115 Surg Oncol Res Fac, Durham, NC 27710
Campus Mail: DUMC Box 2926 Med Ctr, Durham, NC 27710

The activities of the Ferrari Laboratory are based on both independent basic research and immune monitoring studies. The research revolves around three main areas of interest: class I-mediated cytotoxic CD8+ T cell responses, antibody-dependent cellular cytotoxicity (ADCC), gene expression in NK and T cellular subsets upon infection with HIV-1. With continuous funding over the last 11 years from the NIH and Bill & Melinda Gates Foundation along with many other productive collaborations within and outside of Duke, the Ferrari Lab has expanded its focus of research to include the ontogeny of HIV-1 specific immune responses that work by eliminating HIV-1 infected cells and how these can be induced by AIDS vaccine candidates.

Education and Training

  • M.D., University of Genoa (Italy), 1985

Selected Grants

Publications

DREAM Trial Investigators, S., G. R. Dagenais, H. C. Gerstein, R. Holman, A. Budaj, A. Escalante, T. Hedner, et al. “Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.” Diabetes Care 31, no. 5 (May 2008): 1007–14. https://doi.org/10.2337/dc07-1868.

Full Text

D’Souza, P., J. H. Cox, G. Ferrari, N. T. Kunwar, V. Polonis, and M. Sarzotti-Kelsoe. “Endpoint Assays in HIV-1 Vaccine Trials: Functioning in a Good Laboratory Practices Environment.” In Validation of Cell-Based Assays in the GLP Setting: A Practical Guide, 239–75, 2008. https://doi.org/10.1002/9780470987810.ch14.

Full Text

Gorse, Geoffrey J., Lindsey R. Baden, Margaret Wecker, Mark J. Newman, Guido Ferrari, Kent J. Weinhold, Brian D. Livingston, et al. “Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.” Vaccine 26, no. 2 (January 10, 2008): 215–23. https://doi.org/10.1016/j.vaccine.2007.10.061.

Full Text

Russell, Nina D., Barney S. Graham, Michael C. Keefer, M Juliana McElrath, Steve G. Self, Kent J. Weinhold, David C. Montefiori, et al. “Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.” J Acquir Immune Defic Syndr 44, no. 2 (February 1, 2007): 203–12. https://doi.org/10.1097/01.qai.0000248356.48501.ff.

Full Text

Goepfert, Paul A., Georgia D. Tomaras, Helen Horton, David Montefiori, Guido Ferrari, Mark Deers, Gerald Voss, et al. “Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.” Vaccine 25, no. 3 (January 5, 2007): 510–18. https://doi.org/10.1016/j.vaccine.2006.07.050.

Full Text

DREAM Trial Investigators, Rury R., Jackie Bosch, Salim Yusuf, Hertzel C. Gerstein, Janice Pogue, Patrick Sheridan, Gilles Dagenais, et al. “Effect of ramipril on the incidence of diabetes.” N Engl J Med 355, no. 15 (October 12, 2006): 1551–62. https://doi.org/10.1056/NEJMoa065061.

Full Text

Betts, Michael R., Clive M. Gray, Josephine H. Cox, and Guido Ferrari. “Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development.” Expert Rev Vaccines 5, no. 4 (August 2006): 505–16. https://doi.org/10.1586/14760584.5.4.505.

Full Text

Mulligan, M. J., N. D. Russell, C. Celum, J. Kahn, E. Noonan, D. C. Montefiori, G. Ferrari, et al. “Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults.” Aids Res Hum Retroviruses 22, no. 7 (July 2006): 678–83. https://doi.org/10.1089/aid.2006.22.678.

Full Text

Pages